-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
MYD88 and CXCR4 mutations are very common in Waldenstrom's macroglobulinemia (WM) and can affect the disease's performance, prognosis, and/or therapeutic effect.
diagnosis
Researchers prospectively collected matching BM and PB samples from 28 WM patients, and separated a total of 5 different tissue parts for analysis: CD19-enriched BM, unenriched BM, CD19-enriched PB, Unenriched PB, and cfDNA.
The results show that MYD88 and CXCR4 have high sensitivity and specificity in plasma cfDNA of WM patients (including those who have received previous treatment).
In summary, the results of this study indicate that the use of cfDNA represents a non-invasive, convenient and potentially cost-effective method for genotyping WM patients.
Original source:
ncbi.
ncbi.
nlm.
nih.
gov/?term=Demos+MG&cauthor_id=33819355">The Demos G maria ncbi.
nlm.
nih.
gov/33819355/" target="_blank" rel="noopener">the Cell-Free Analysis for Detection of the DNA and of CXCR4 S338X MYD88 L265P mutations in Waldenström macroglobulinemia in this message